NCT06160921

Brief Summary

The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; Guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50,000

participants targeted

Target at P75+ for all trials

Timeline
45mo left

Started Jan 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress63%
Jan 2020Jan 2030

Study Start

First participant enrolled

January 1, 2020

Completed
3.9 years until next milestone

First Submitted

Initial submission to the registry

November 29, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

December 7, 2023

Completed
6.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2030

Last Updated

March 28, 2024

Status Verified

March 1, 2024

Enrollment Period

10 years

First QC Date

November 29, 2023

Last Update Submit

March 26, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Resistant hypertension

    10 years of follow-up Resistant hypertension occurred during this period

  • Death (all-cause mortality, mortality from hypertension complications)

    10 years of follow-up deaths occurred during this period

Secondary Outcomes (1)

  • Major adverse cardiovascular events

    10 years of follow-up deaths occurred during this period

Study Arms (1)

2

Other: Standard therapy

Interventions

Individualized blood pressure reduction program

2

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University

You may qualify if:

  • A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University

You may not qualify if:

  • Patients with secondary hypertension, patients with liver and kidney dysfunction,
  • patients with mental disorders, and patients who are unwilling to participate in this trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The First Affiliated Hospital of Xinjiang Medicial University

Ürümqi, Xinjiang, 830000, China

RECRUITING

MeSH Terms

Conditions

Hypertension

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Central Study Contacts

Xiang Xie, Phd

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Xiangxie, MD,The First Affiliated Hospital Of XinJiang Medicial University

Study Record Dates

First Submitted

November 29, 2023

First Posted

December 7, 2023

Study Start

January 1, 2020

Primary Completion (Estimated)

January 1, 2030

Study Completion (Estimated)

January 1, 2030

Last Updated

March 28, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations